AIM ImmunoTech enters $1.5M manufacturing agreement with Sterling Pharma for Ampligen drug substance

AIM ImmunoTech Inc.

Agreement with Sterling Pharma Solutions to manufacture PolyI and Poly C12U (precursors to Ampligen) at Dudley, UK site.
Estimated cost ~$1.5M over 12 months; includes process development, non-GMP demo batches, analytical method validation, and one cGMP batch each.
Product intended for ongoing and future clinical trials, including potential Phase 3 for metastatic pancreatic cancer.
Shareholder director nominations for 2026 annual meeting must be received between Aug 18 and Sep 17, 2026; universal proxy deadline Oct 19, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.